Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Curis LifesciencesNSE:CURIS +2.44%21 Receivables Turnover is 6.42 as of Mar. 2026. GuruFocus rates NSE:CURIS with a GF Score™ of 21/100. The stock has 3 warning signs investors should review. Among 947 Drug Manufacturers companies, Curis Lifesciences ranks better than 66.95% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Curis Lifesciences's Revenue for the
six
months ended in Mar. 2026 was ₹601.6 Mil. Curis Lifesciences's average Accounts Receivable for the
six
months ended in Mar. 2026 was ₹93.7 Mil.
Hence, Curis Lifesciences's Receivables Turnover for the
six
months ended in Mar. 2026 was 6.42.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Curis Lifesciences Receivables Turnover Related Terms
Curis Lifesciences Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Curis Lifesciences's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Curis Lifesciences Receivables Turnover Chart
Curis Lifesciences Annual Data
Trend
Mar23
Mar24
Mar25
Mar26
Receivables Turnover
3.71
3.62
5.43
6.42
Curis Lifesciences Semi-Annual Data
Mar23
Mar24
Mar25
Mar26
Receivables Turnover
3.71
3.62
5.43
6.42
NSE:CURIS vs ZTS: Receivables Turnover Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Curis Lifesciences's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Curis Lifesciences Receivables Turnover vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Curis Lifesciences's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Curis Lifesciences's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Curis Lifesciences (NSE:CURIS) has a Receivables Turnover of 6.42 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Curis Lifesciences and its competitors. According to the industry distribution chart, Curis Lifesciences ranks #313 out of 947 companies in the Drug Manufacturers industry, placing it in the top 33.1%.
Is Curis Lifesciences' Receivables Turnover too high?
Curis Lifesciences' current Receivables Turnover is 6.42. The Drug Manufacturers industry median Receivables Turnover is 5.08. Curis Lifesciences' value of 6.42 is 26.4% above this industry median. Based on the distribution chart, Curis Lifesciences ranks #313 out of 947 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Curis Lifesciences has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Curis Lifesciences' Receivables Turnover compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Curis Lifesciences ranks #313 out of 947 companies for Receivables Turnover. This puts Curis Lifesciences in the upper half of its industry. The industry median Receivables Turnover is 5.08. Curis Lifesciences' value of 6.42 is 26.4% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Drug Manufacturers company?
The median Receivables Turnover among Drug Manufacturers companies is 5.08, based on 947 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Curis Lifesciences's current Receivables Turnover of 6.42 is 26.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Curis Lifesciences and its competitors. For the Drug Manufacturers industry, the median Receivables Turnover is 5.08 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Curis Lifesciences's current Receivables Turnover is 6.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Curis Lifesciences stock overvalued right now?
Curis Lifesciences (NSE:CURIS) has a current Receivables Turnover of 6.42. The current Receivables Turnover is 6.42 and 26.4% above the Drug Manufacturers industry median of 5.08. Curis Lifesciences' overall GF Score™ is 21/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Curis Lifesciences (NSE:CURIS), the current Receivables Turnover is 6.42 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Curis Lifesciences Ltd is in the business of manufacturing of pharmaceutical products. It specializes in the manufacturing of a wide range of pharmaceutical products such as Tablets, Capsules, External Preparations, Oral liquid, and Sterile Ophthalmic Ointments. The company's business verticals are: Loan License manufacturing, Contract Manufacturing, and Direct Export. The company derives revenue from the sale of its pharmaceutical products.
21GF Score
Get the complete analysis for NSE:CURIS
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:CURIS has been successfully added to your 
